Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332:1050 (6 May), doi:10.1136/bmj.332.7549.1050-a
London Owen Dyer
The lobbying group of the US drug industry, Pharmaceutical Research and Manufacturers of America (PhRMA), last week won two spoof awards from a watchdog that tracks aggressive and misleading marketing by the industry.
PhRMA led the field in the second annual Bitter Pill awards, winning prizes in two categories from the Prescription Access Litigation Project, a national umbrella organisation of 118 consumer health advocacy groups.
Aggressive marketing is driving up health costs and encouraging patients to take drugs they do not need, argued Jerry Avorn, a professor at Harvard Medical School and one of the organisers of the awards. “As a physician I have seen how the avalanche of direct to consumer drug advertising infects the doctor-patient relationship,” he said.
The first of the two awards was for the organisation’s guidelines on direct to consumer advertising, which the consumer pressure group claimed were ineffective, not least because
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses